Bevacizumab

eMC §4.2 (Abevmy 25 mg/ml) — must be given under the supervision of a physician experienced in antineoplastic medicinal products; dose reduction for adverse reactions is not recommended (suspend or discontinue instead). Indication-specific dosing: Metastatic colorectal cancer (mCRC) 5 or 10 mg/kg every 2 weeks, or 7.5 or 15 mg/kg every 3 weeks. Metastatic breast cancer 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks. Non-squamous NSCLC 7.5 or 15 mg/kg every 3 weeks (with platinum-based chemo, up to 6 cycles then single agent); with erlotinib 15 mg/kg every 3 weeks. Metastatic renal cell cancer 10 mg/kg every 2 weeks. Epithelial ovarian/fallopian tube/primary peritoneal cancer 15 mg/kg every 3 weeks (front-line and platinum-sensitive recurrent), or 10 mg/kg every 2 weeks (platinum-resistant; 15 mg/kg every 3 weeks when combined with topotecan given days 1-5). Cervical cancer 15 mg/kg every 3 weeks. Continue until disease progression or unacceptable toxicity (front-line ovarian capped at max 15 months). Administration: initial dose over 90 minutes; if tolerated, second over 60 minutes, subsequent over 30 minutes. Not an IV push/bolus; do not mix with glucose solutions. Do not initiate for at least 28 days following major surgery or until the surgical wound is fully healed. No dose adjustment in patients >=65 years; safety/efficacy not studied in renal or hepatic impairment. US labelling (MVASI) also lists recurrent glioblastoma 10 mg/kg every 2 weeks.